These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1063 related articles for article (PubMed ID: 18695050)

  • 1. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.
    Leinonen V; Alafuzoff I; Aalto S; Suotunen T; Savolainen S; Någren K; Tapiola T; Pirttilä T; Rinne J; Jääskeläinen JE; Soininen H; Rinne JO
    Arch Neurol; 2008 Oct; 65(10):1304-9. PubMed ID: 18695050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.
    Ikonomovic MD; Klunk WE; Abrahamson EE; Mathis CA; Price JC; Tsopelas ND; Lopresti BJ; Ziolko S; Bi W; Paljug WR; Debnath ML; Hope CE; Isanski BA; Hamilton RL; DeKosky ST
    Brain; 2008 Jun; 131(Pt 6):1630-45. PubMed ID: 18339640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [11C]PIB PET Is Associated with the Brain Biopsy Amyloid-β Load in Subjects Examined for Normal Pressure Hydrocephalus.
    Rinne JO; Suotunen T; Rummukainen J; Herukka SK; Nerg O; Koivisto AM; Rauramaa T; Någren K; Hiltunen M; Alafuzoff I; Rinne J; Jääskeläinen JE; Soininen H; Leinonen V
    J Alzheimers Dis; 2019; 67(4):1343-1351. PubMed ID: 30689567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biopsy support for the validity of Pittsburgh compound B positron emission tomography with a twist.
    Klunk WE
    Arch Neurol; 2008 Oct; 65(10):1281-3. PubMed ID: 18852340
    [No Abstract]   [Full Text] [Related]  

  • 5. S-[18F]THK-5117-PET and [11C]PIB-PET Imaging in Idiopathic Normal Pressure Hydrocephalus in Relation to Confirmed Amyloid-β Plaques and Tau in Brain Biopsies.
    Leinonen V; Rauramaa T; Johansson J; Bottelbergs A; Tesseur I; van der Ark P; Pemberton D; Koivisto AM; Jääskeläinen JE; Hiltunen M; Herukka SK; Blennow K; Zetterberg H; Jokinen P; Rokka J; Helin S; Haaparanta-Solin M; Solin O; Okamura N; Kolb HC; Rinne JO
    J Alzheimers Dis; 2018; 64(1):171-179. PubMed ID: 29865068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.
    Okamura N; Furumoto S; Fodero-Tavoletti MT; Mulligan RS; Harada R; Yates P; Pejoska S; Kudo Y; Masters CL; Yanai K; Rowe CC; Villemagne VL
    Brain; 2014 Jun; 137(Pt 6):1762-71. PubMed ID: 24681664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
    Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
    Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET.
    Verhoeff NP; Wilson AA; Takeshita S; Trop L; Hussey D; Singh K; Kung HF; Kung MP; Houle S
    Am J Geriatr Psychiatry; 2004; 12(6):584-95. PubMed ID: 15545326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease.
    Wiley CA; Lopresti BJ; Venneti S; Price J; Klunk WE; DeKosky ST; Mathis CA
    Arch Neurol; 2009 Jan; 66(1):60-7. PubMed ID: 19139300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study.
    Ikonomovic MD; Abrahamson EE; Price JC; Hamilton RL; Mathis CA; Paljug WR; Debnath ML; Cohen AD; Mizukami K; DeKosky ST; Lopez OL; Klunk WE
    Acta Neuropathol; 2012 Mar; 123(3):433-47. PubMed ID: 22271153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.
    Buckley RF; Hanseeuw B; Schultz AP; Vannini P; Aghjayan SL; Properzi MJ; Jackson JD; Mormino EC; Rentz DM; Sperling RA; Johnson KA; Amariglio RE
    JAMA Neurol; 2017 Dec; 74(12):1455-1463. PubMed ID: 28973551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
    Betthauser TJ; Koscik RL; Jonaitis EM; Allison SL; Cody KA; Erickson CM; Rowley HA; Stone CK; Mueller KD; Clark LR; Carlsson CM; Chin NA; Asthana S; Christian BT; Johnson SC
    Brain; 2020 Jan; 143(1):320-335. PubMed ID: 31886494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques.
    Driscoll I; Troncoso JC; Rudow G; Sojkova J; Pletnikova O; Zhou Y; Kraut MA; Ferrucci L; Mathis CA; Klunk WE; O'Brien RJ; Davatzikos C; Wong DF; Resnick SM
    Acta Neuropathol; 2012 Dec; 124(6):823-31. PubMed ID: 22864813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography with [18F]flutemetamol and [11C]PiB for in vivo detection of cerebral cortical amyloid in normal pressure hydrocephalus patients.
    Leinonen V; Rinne JO; Virtanen KA; Eskola O; Rummukainen J; Huttunen J; von Und Zu Fraunberg M; Nerg O; Koivisto AM; Rinne J; Jääskeläinen JE; Buckley C; Smith A; Jones PA; Sherwin P; Farrar G; McLain R; Kailajärvi M; Heurling K; Grachev ID
    Eur J Neurol; 2013 Jul; 20(7):1043-52. PubMed ID: 23398333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.
    Kadir A; Marutle A; Gonzalez D; Schöll M; Almkvist O; Mousavi M; Mustafiz T; Darreh-Shori T; Nennesmo I; Nordberg A
    Brain; 2011 Jan; 134(Pt 1):301-17. PubMed ID: 21149866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease.
    Cody KA; Langhough RE; Zammit MD; Clark L; Chin N; Christian BT; Betthauser TJ; Johnson SC
    Brain; 2024 Jun; 147(6):2144-2157. PubMed ID: 38667631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication.
    Remes AM; Laru L; Tuominen H; Aalto S; Kemppainen N; Mononen H; Någren K; Parkkola R; Rinne JO
    Arch Neurol; 2008 Apr; 65(4):540-4. PubMed ID: 18413480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.
    Ikonomovic MD; Buckley CJ; Abrahamson EE; Kofler JK; Mathis CA; Klunk WE; Farrar G
    Acta Neuropathol; 2020 Oct; 140(4):463-476. PubMed ID: 32772265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies.
    Rinne JO; Wong DF; Wolk DA; Leinonen V; Arnold SE; Buckley C; Smith A; McLain R; Sherwin PF; Farrar G; Kailajärvi M; Grachev ID
    Acta Neuropathol; 2012 Dec; 124(6):833-45. PubMed ID: 23053137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury.
    Hong YT; Veenith T; Dewar D; Outtrim JG; Mani V; Williams C; Pimlott S; Hutchinson PJ; Tavares A; Canales R; Mathis CA; Klunk WE; Aigbirhio FI; Coles JP; Baron JC; Pickard JD; Fryer TD; Stewart W; Menon DK
    JAMA Neurol; 2014 Jan; 71(1):23-31. PubMed ID: 24217171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.